JBI-802

DRUG3 trials

Sponsors

Jubilant Therapeutics Inc., The Christ Hospital

Conditions

Essential Thrombocythemia (ET)Locally Advanced Solid TumorLung Cancer (NSCLC)Metastatic Solid TumorMyelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Myeloproliferative Neoplasms (MPN)

Phase 1

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Jubilant Therapeutics Inc.Locally Advanced Solid Tumor, Metastatic Solid Tumor

Start: 2022-04-08End: 2025-08-31Target: 126Updated: 2023-06-15

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

RecruitingNCT07612280

Jubilant Therapeutics Inc.Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Myeloproliferative Neoplasms (MPN)

Start: 2024-10-21End: 2028-09-15Target: 30Updated: 2026-06-03

Phase 2

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

RecruitingNCT07207395

The Christ HospitalLung Cancer (NSCLC)

Start: 2025-04-29End: 2028-10-31Target: 30Updated: 2025-10-06

Related Papers

Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1/HDAC6): An opportunity to treat essential thrombocythemia and MPN/MDS patients with thrombocytosis in ongoing phase 1/2 clinical trial.

Journal of Clinical Oncology2025-05-281 citations